Clinical Report: Comparative Analysis of Hemorrhagic Transformation Imaging
Overview
This study compares hemorrhagic transformation severity following tenecteplase and alteplase in acute ischemic stroke patients. No significant differences in symptomatic intracranial hemorrhage (sICH) or hemorrhagic severity were found between the two treatments, with a total of 95 patients included (alteplase n=41; tenecteplase n=54).
Background
Intravenous thrombolysis is critical for treating acute ischemic stroke, with alteplase being the traditional agent. Tenecteplase is gaining traction due to its favorable pharmacokinetics.
Data Highlights
Characteristic
Alteplase (n=41)
Tenecteplase (n=54)
sICH Incidence
No significant difference
No significant difference
Higher NIHSS Score
OR 1.10 (95% CI 1.02–1.18, p=0.013)
Longer ONT
OR 1.12 per 10 min (95% CI 1.02–1.23, p=0.016)
Key Findings
No significant difference in sICH incidence between tenecteplase and alteplase.
Remote hemorrhagic phenotypes were numerically more frequent in the tenecteplase group, though not statistically significant.
No significant ordinal shift in hemorrhagic transformation severity was detected.
Higher baseline NIHSS score and longer ONT were independent predictors of intracranial hemorrhage.
Thrombolytic agent type did not independently affect hemorrhagic outcomes.
Clinical Implications
The findings suggest that tenecteplase does not lead to an increased risk of hemorrhagic transformation compared to alteplase in a real-world setting. Clinicians should consider these results when selecting thrombolytic therapy for acute ischemic stroke.
Conclusion
This exploratory study indicates that tenecteplase is not associated with a higher incidence of hemorrhagic events compared to alteplase.
